Trial Profile
An International, Randomised, Double Blinded, Multi-centre, Active- and Placebo-controlled Dose Response Trial to Evaluate the Efficacy and Safety of SABER-Bupivacaine for Postoperative Pain Control in Patients Following Arthroscopic Shoulder Surgery
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Jul 2022
Price :
$35
*
At a glance
- Drugs Bupivacaine (Primary) ; Bupivacaine (Primary)
- Indications Postoperative pain
- Focus Registrational; Therapeutic Use
- Sponsors DURECT Corporation
- 06 Jul 2022 According to an Innocoll Pharmaceuticals media release, Sten Rasmussen, MD PhD, Professor and Head of Department of Clinical Medicine, Aalborg University, Denmark, the senior author and a principal investigator of this study.
- 06 Jul 2022 According to an Innocoll Pharmaceuticals media release, data from this study were published online in the Journal of the American Academy of Orthopedic Surgeons (AAOS) Global Research & Reviews on May 17, 2022.
- 06 Jul 2022 Results presented in an Innocoll Pharmaceuticals media release